Marshall Wace, LLP Dia Medica Therapeutics Inc. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.56 - $4.4 $68,467 - $117,678	26,745 New	26,745 $69,000
Q1 2022 May 16, 2022	SELL	$2.29 - $3.88 $22,970 - $38,920	-10,031 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.1 - $4.32 $451,456 - $629,125	-145,631 Reduced 93.56%	10,031 $40,000
Q2 2021 Aug 13, 2021	BUY	$4.45 - $9.91 $354,642 - $789,777	79,695 Added 104.91%	155,662 $693,000
Q1 2021 May 17, 2021	BUY	$7.76 - $10.43 $124,904 - $167,881	16,096 Added 26.88%	75,967 $695,000
Q4 2020 Feb 16, 2021	BUY	$4.13 - $10.14 $247,267 - $607,091	59,871 New	59,871 $607,000

3.87M

1.3K

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $116M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.